“Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials With VP-102 CAMP-1 and CAMP-2”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s92, https://doi.org/10.25251/skin.5.supp.92.